Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216521 · ClinicalTrials.gov registry record
Intent of Surgery for IPMN
A clinical trial of Intraductal Papillary Mucinous Neoplasm, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 14
- Study locations
NCT07216521 is a study of Intraductal Papillary Mucinous Neoplasm that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 2,000 participants, above the 1,781-participant average among 4 other Intraductal Papillary Mucinous Neoplasm trials with a reported enrollment target (12% higher). The trial reports 14 study locations across 8 states.
The verdict
NCT07216521, a study of Intraductal Papillary Mucinous Neoplasm, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on pathology. 2. Compare clinicopathologic features and outcomes between surveillance-detected and incidentally detected IPMN-derived pancreatic cancers. 3. Revise and redefine risk features limited to patients undergoing surgery for IPMN-related indications, identifying optimal predictors of malignant IPMN (high-grade dysplasia or invasive cancer).
Conditions Studied
Study Locations (14)
Other
- Nanjing University - Nanjing
- Heidelberg University - Heidelberg
- San Raffaele Hospital - Milan
- Padua University - Padua
- University of Amsterdam - Amsterdam
- University of Utrecht - Utrecht
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering - New York
Arizona
- Mayo Clinic - Phoenix
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke University - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216521
The ClinicalTrials.gov registry entry for NCT07216521 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,781-participant average among 4 other Intraductal Papillary Mucinous Neoplasm trials with a reported enrollment target (12% higher). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intraductal Papillary Mucinous Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT07216521 reports 14 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT07216521 about?
NCT07216521 is a clinical study titled "Intent of Surgery for IPMN". This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on p...
What is the current status of trial NCT07216521?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2025-09-15. Estimated completion is 2025-12.
What conditions does trial NCT07216521 study?
This clinical trial studies the following conditions: Intraductal Papillary Mucinous Neoplasm.
Who is sponsoring clinical trial NCT07216521?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216521 being conducted?
This trial has 14 study locations across Arizona, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intraductal Papillary Mucinous Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.